NCT02807272 2024-07-17
CMML/AML
Kura Oncology, Inc.
Phase 2 Completed
Clinical Trials
6 trialsNCT02464228 2024-06-26
PTCL
Kura Oncology, Inc.
Phase 2 Completed
NCT03719690 2024-06-21
AIM-HN/SEQ-HN
Kura Oncology, Inc.
Phase 2 Completed
NCT00050141 2013-02-01
Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced Breast Cancer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed
NCT00354146 2011-02-01
A Phase 2 Study of Farnesyl Transferase Inhibitor (R115777, Tipifarnib) in Patients With Refractory or Relapsed Acute Myeloid Leukemia.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed
NCT00048503 2010-04-27
Study of Tipifarnib as Postconsolidation Therapy for Acute Myeloid Leukemia in Patients 60 Years and Older
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed